An Adaptive Two-Part Phase 2, Multi-Center, Randomized, Double Blind, Placebo-Controlled Study to Assess the Safety, Efficacy, and Pharmacokinetics of Multiple Doses of ION224 Administered Once Monthly in Adult Subjects with Confirmed Non-Alcoholic Steatohepatitis

To assess the effects of multiple ION224 doses when administered subcutaneously (SC) for 49 weeks (12 months) on NASH histologic improvement, i.e., proportion of subjects achieving at the End of the Treatment at least a 2-point reduction in NAFLD Activity Score (NAS), with at least 1-point improvement in hepatocellular ballooning or lobular inflammation, and without worsening in fibrosis stage.